140 related articles for article (PubMed ID: 30088909)
1. Engineering Anticancer Amphipathic Peptide-Dendronized Compounds for Highly-Efficient Plasma/Organelle Membrane Perturbation and Multidrug Resistance Reversal.
Zhang X; Li Y; Hu C; Wu Y; Zhong D; Xu X; Gu Z
ACS Appl Mater Interfaces; 2018 Sep; 10(37):30952-30962. PubMed ID: 30088909
[TBL] [Abstract][Full Text] [Related]
2. Pro-apoptotic cationic host defense peptides rich in lysine or arginine to reverse drug resistance by disrupting tumor cell membrane.
Dai Y; Cai X; Shi W; Bi X; Su X; Pan M; Li H; Lin H; Huang W; Qian H
Amino Acids; 2017 Sep; 49(9):1601-1610. PubMed ID: 28664269
[TBL] [Abstract][Full Text] [Related]
3. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
Kars MD; Işeri OD; Gunduz U; Molnar J
Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
[TBL] [Abstract][Full Text] [Related]
4. Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells.
Shi Q; Zhang L; Liu M; Zhang X; Zhang X; Xu X; Chen S; Li X; Zhang J
Biomaterials; 2015 Oct; 67():169-82. PubMed ID: 26218743
[TBL] [Abstract][Full Text] [Related]
5. Aliphatic acid-conjugated antimicrobial peptides--potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability.
Deng X; Qiu Q; Ma K; Wang X; Huang W; Qian H
Org Biomol Chem; 2015 Jul; 13(28):7673-80. PubMed ID: 26083110
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Specific Multiple Stimuli-Activated Dendrimeric Nanoassemblies with Metabolic Blockade Surmount Chemotherapy Resistance.
Li Y; Xu X; Zhang X; Li Y; Zhang Z; Gu Z
ACS Nano; 2017 Jan; 11(1):416-429. PubMed ID: 28005335
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of Novel Cholesteryl Peptides with Anticancer and Multidrug Resistance-Reversing Activities.
Deng X; Qiu Q; Wang X; Huang W; Qian H
Chem Biol Drug Des; 2016 Mar; 87(3):374-81. PubMed ID: 26390861
[TBL] [Abstract][Full Text] [Related]
9. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
11. ROS-triggered and regenerating anticancer nanosystem: an effective strategy to subdue tumor's multidrug resistance.
Su Z; Chen M; Xiao Y; Sun M; Zong L; Asghar S; Dong M; Li H; Ping Q; Zhang C
J Control Release; 2014 Dec; 196():370-83. PubMed ID: 25278256
[TBL] [Abstract][Full Text] [Related]
12. Supramolecularly self-assembled nano-twin drug for reversing multidrug resistance.
Wu C; Xu L; Shi L; Gao X; Li J; Zhu X; Zhang C
Biomater Sci; 2018 Jul; 6(8):2261-2269. PubMed ID: 29999073
[TBL] [Abstract][Full Text] [Related]
13. Reversal effect of Tween-20 on multidrug resistance in tumor cells in vitro.
Yang S; Liu J; Chen Y; Jiang J
Biomed Pharmacother; 2012 Apr; 66(3):187-94. PubMed ID: 22440896
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel peptides based on antimicrobial peptides as potential agents with antitumor and multidrug resistance-reversing activities.
Zhang B; Shi W; Li J; Liao C; Yang L; Huang W; Qian H
Chem Biol Drug Des; 2017 Nov; 90(5):972-980. PubMed ID: 28524273
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives.
Bisi A; Meli M; Gobbi S; Rampa A; Tolomeo M; Dusonchet L
Bioorg Med Chem; 2008 Jul; 16(13):6474-82. PubMed ID: 18522868
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.
Liang JF; Yang VC
Bioorg Med Chem Lett; 2005 Nov; 15(22):5071-5. PubMed ID: 16168650
[TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
Wang ZD; Wang RZ; Xia YZ; Kong LY; Yang L
Chin J Nat Med; 2018 Jan; 16(1):20-28. PubMed ID: 29425587
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents.
Zou ZH; Lan XB; Qian H; Huang WL; Li YM
Bioorg Med Chem Lett; 2011 Oct; 21(19):5934-8. PubMed ID: 21843940
[TBL] [Abstract][Full Text] [Related]
19. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
Li H; Krstin S; Wink M
Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds.
Gruber L; Abdelfatah S; Fröhlich T; Reiter C; Klein V; Tsogoeva SB; Efferth T
Molecules; 2018 Apr; 23(4):. PubMed ID: 29642419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
